RT Journal Article
T1 The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response.
A1 Sánchez-Alcoholado, Lidia
A1 Ramos-Molina, Bruno
A1 Otero, Ana
A1 Laborda-Illanes, Aurora
A1 Ordóñez, Rafael
A1 Medina, José Antonio
A1 Gómez-Millán, Jaime
A1 Queipo-Ortuño, María Isabel
K1 colorectal cancer
K1 dietary fiber
K1 dysbiosis
K1 gut microbiota
K1 inflammation
K1 polyamines
K1 polyphenols
K1 polyunsaturated fatty acids
K1 probiotics
K1 short-chain fatty acids
AB Colorectal cancer (CRC) is the third most common cancer worldwide and the leading cause of cancer-related deaths. Recently, several studies have demonstrated that gut microbiota can alter CRC susceptibility and progression by modulating mechanisms such as inflammation and DNA damage, and by producing metabolites involved in tumor progression or suppression. Dysbiosis of gut microbiota has been observed in patients with CRC, with a decrease in commensal bacterial species (butyrate-producing bacteria) and an enrichment of detrimental bacterial populations (pro-inflammatory opportunistic pathogens). CRC is characterized by altered production of bacterial metabolites directly involved in cancer metabolism including short-chain fatty acids and polyamines. Emerging evidence suggests that diet has an important impact on the risk of CRC development. The intake of high-fiber diets and the supplementation of diet with polyunsaturated fatty acids, polyphenols and probiotics, which are known to regulate gut microbiota, could be not only a potential mechanism for the reduction of CRC risk in a primary prevention setting, but may also be important to enhance the response to cancer therapy when used as adjuvant to conventional treatment for CRC. Therefore, a personalized modulation of the pattern of gut microbiome by diet may be a promising approach to prevent the development and progression of CRC and to improve the efficacy of antitumoral therapy.
SN 2072-6694
YR 2020
FD 2020-05-29
LK https://hdl.handle.net/10668/26734
UL https://hdl.handle.net/10668/26734
LA en
DS RISalud
RD Apr 6, 2025